Moreover, a large number of clinical trials of novel targeted drugs are underway in patients with HER2low breast cancer [14]; the results are yet to be published to date, but some novel HER2-targeted agents (NCT02277717, NCT03734029) and antitumor vaccines (NCT01570036, NCT01570036) have shown promising activity in HER2low TNBC patients. Here, ERBB2 is linked to breast cancer.